BCR-ABL peptide vaccination in healthy subjects: Immunological responses are equivalent to those in chronic myeloid leukaemia patients

Leukemia Research

Volumn 35, Issue 3, 2011, Pages 369-372

  Rojas, José M ^a   Knight, Katy ^a   Watmough, Sarah ^a   Bell, Joanne ^a   Wang, Lihui ^a   Callaghan, Therese ^b   Clark, Richard E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

BCR ABL; CML; Healthy subjects; T cells; Vaccine

Indexed keywords

GAMMA INTERFERON; GLYCYLPHENYLALANYLLYSYLGLUTAMINYLSERYLSERYLLYSYLALANYLLEUCINE; GLYCYLPHENYLALANYLLYSYLGLUTAMINYLSERYLSERYLLYSYLALANYLLEUCYLGLUTAMINYLARGINYLPROPYLVALINE; GRANZYME B; LYSYLGLUTAMINYLSERYLSERYLLYSYLALANYLLEUCYLGLUTAMINYLARGININE; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INJECTION SITE REACTION; NORMAL HUMAN; PRIORITY JOURNAL;

CANCER VACCINES; CASE-CONTROL STUDIES; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FUSION PROTEINS, BCR-ABL; GRANZYMES; HUMANS; INTERFERON-GAMMA; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PEPTIDE FRAGMENTS; PROGNOSIS; T-LYMPHOCYTES;

EID: 79951780053     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.05.028     Document Type: Article

References (15)

1. Clark R.E., Christmas S.E. BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia. Leukemia and Lymphoma 2001, 42:871-880.
2. Bocchia M., Wentworth P.A., Southwood S., Sidney J., McGraw K., Scheinberg D.A., et al. Specific binding of leukemia oncogene fusion protein peptides to HLA Class I molecules. Blood 1995, 85:2680-2684.
3. Clark R.E., Dodi I.A., Hill S.C., Lill J.R., Aubert G., Macintyre A.R., et al. Direct evidence that leukaemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001, 98:2887-2893.
4. Cathcart K., Pinilla-Ibarz J., Korontsvit T., Schwartz J., Zakhaleva V., Papadopoulos E.B., et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004, 103:1037-1042.
5. Bocchia M., Gentili S., Abruzzese E., Fanelli A., Iuliano F., Tabilio A., et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005, 365:657-662.
6. Rojas J.M., Knight K., Wang L., Clark R.E. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007, 21:2287-2295.
7. Alexander J., Sidney J., Southwood S., Ruppert J., Oseroff C., Maewal A., et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994, 1:751-761.
8. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
9. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27:5904-5912.
10. Rojas J.M., Knight K., Wang L.H., Clark R.E. BCR-ABL peptide vaccination does not induce tolerance in CML patients: Evidence from the EPIC trial. Haematologica 2008, 93(Suppl. 1):239. Abstract 0591.
11. Gannagé M., Abel M., Michallet A.S., Delluc S., Lambert M., Giraudier S., et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. Journal of Immunology 2005, 174:8210-8218.
12. Molldrem J.J., Lee P.P., Wang C., Felio K., Kantarjian H.M., Champlin R.E., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine 2000, 6:1018-1023.
13. Rosenfeld C., Cheever M.A., Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 2003, 17:1301-1312.
14. Oka Y., Tsuboi A., Oji Y., Kawase I., Sugiyama H. WT1 peptide vaccine for the treatment of cancer. Current Opinion in Immunology 2008, 20:211-220.
15. Rezvani K. PR1 vaccination in myeloid malignancies. Expert Review of Vaccines 2008, 7:867-875.